Dongze Zhang1, Huiyin Tu1, Chaojun Wang1,2, Liang Cao1,3, Wenfeng Hu1, Bryan T Hackfort4, Robert L Muelleman1, Michael C Wadman1, Yu-Long Li1,4. 1. Department of Emergency Medicine, University of Nebraska Medical Center, 985850 Nebraska Medical Center, Omaha, NE 68198-5850, USA. 2. Department of Cardiovascular Disease, the First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shaanxi, 710061, China. 3. Department of Cardiac Surgery, Second Xiangya Hospital, Central South University, Changsha 410011, China. 4. Department of Cellular & Integrative Physiology, University of Nebraska Medical Center, Omaha, NE 68198, USA.
Abstract
AIMS: Cardiac sympathetic overactivation is an important trigger of ventricular arrhythmias in patients with chronic heart failure (CHF). Our previous study demonstrated that N-type calcium (Cav2.2) currents in cardiac sympathetic post-ganglionic (CSP) neurons were increased in CHF. This study investigated the contribution of Cav2.2 channels in cardiac sympathetic overactivation and ventricular arrhythmogenesis in CHF. METHODS AND RESULTS: Rat CHF was induced by surgical ligation of the left coronary artery. Lentiviral Cav2.2-α shRNA or scrambled shRNA was transfected in vivo into stellate ganglia (SG) in CHF rats. Final experiments were performed at 14 weeks after coronary artery ligation. Real-time polymerase chain reaction and western blot data showed that in vivo transfection of Cav2.2-α shRNA reduced the expression of Cav2.2-α mRNA and protein in the SG in CHF rats. Cav2.2-α shRNA also reduced Cav2.2 currents and cell excitability of CSP neurons and attenuated cardiac sympathetic nerve activities (CSNA) in CHF rats. The power spectral analysis of heart rate variability (HRV) further revealed that transfection of Cav2.2-α shRNA in the SG normalized CHF-caused cardiac sympathetic overactivation in conscious rats. Twenty-four-hour continuous telemetry electrocardiogram recording revealed that this Cav2.2-α shRNA not only decreased incidence and duration of ventricular tachycardia/ventricular fibrillation but also improved CHF-induced heterogeneity of ventricular electrical activity in conscious CHF rats. Cav2.2-α shRNA also decreased susceptibility to ventricular arrhythmias in anaesthetized CHF rats. However, Cav2.2-α shRNA failed to improve CHF-induced cardiac contractile dysfunction. Scrambled shRNA did not affect Cav2.2 currents and cell excitability of CSP neurons, CSNA, HRV, and ventricular arrhythmogenesis in CHF rats. CONCLUSIONS: Overactivation of Cav2.2 channels in CSP neurons contributes to cardiac sympathetic hyperactivation and ventricular arrhythmogenesis in CHF. This suggests that discovering purely selective and potent small-molecule Cav2.2 channel blockers could be a potential therapeutic strategy to decrease fatal ventricular arrhythmias in CHF. Published on behalf of the European Society of Cardiology. All rights reserved.
AIMS: Cardiac sympathetic overactivation is an important trigger of ventricular arrhythmias in patients with chronic heart failure (CHF). Our previous study demonstrated that N-type calcium (Cav2.2) currents in cardiac sympathetic post-ganglionic (CSP) neurons were increased in CHF. This study investigated the contribution of Cav2.2 channels in cardiac sympathetic overactivation and ventricular arrhythmogenesis in CHF. METHODS AND RESULTS:Rat CHF was induced by surgical ligation of the left coronary artery. Lentiviral Cav2.2-α shRNA or scrambled shRNA was transfected in vivo into stellate ganglia (SG) in CHFrats. Final experiments were performed at 14 weeks after coronary artery ligation. Real-time polymerase chain reaction and western blot data showed that in vivo transfection of Cav2.2-α shRNA reduced the expression of Cav2.2-α mRNA and protein in the SG in CHFrats. Cav2.2-α shRNA also reduced Cav2.2 currents and cell excitability of CSP neurons and attenuated cardiac sympathetic nerve activities (CSNA) in CHFrats. The power spectral analysis of heart rate variability (HRV) further revealed that transfection of Cav2.2-α shRNA in the SG normalized CHF-caused cardiac sympathetic overactivation in conscious rats. Twenty-four-hour continuous telemetry electrocardiogram recording revealed that this Cav2.2-α shRNA not only decreased incidence and duration of ventricular tachycardia/ventricular fibrillation but also improved CHF-induced heterogeneity of ventricular electrical activity in conscious CHFrats. Cav2.2-α shRNA also decreased susceptibility to ventricular arrhythmias in anaesthetized CHFrats. However, Cav2.2-α shRNA failed to improve CHF-induced cardiac contractile dysfunction. Scrambled shRNA did not affect Cav2.2 currents and cell excitability of CSP neurons, CSNA, HRV, and ventricular arrhythmogenesis in CHFrats. CONCLUSIONS: Overactivation of Cav2.2 channels in CSP neurons contributes to cardiac sympathetic hyperactivation and ventricular arrhythmogenesis in CHF. This suggests that discovering purely selective and potent small-molecule Cav2.2 channel blockers could be a potential therapeutic strategy to decrease fatal ventricular arrhythmias in CHF. Published on behalf of the European Society of Cardiology. All rights reserved.
Authors: Silvia G Priori; Carina Blomström-Lundqvist; Andrea Mazzanti; Nico Blom; Martin Borggrefe; John Camm; Perry Mark Elliott; Donna Fitzsimons; Robert Hatala; Gerhard Hindricks; Paulus Kirchhof; Keld Kjeldsen; Karl-Heinz Kuck; Antonio Hernandez-Madrid; Nikolaos Nikolaou; Tone M Norekvål; Christian Spaulding; Dirk J Van Veldhuisen Journal: G Ital Cardiol (Rome) Date: 2016-02
Authors: Masahiro Ogawa; Shengmei Zhou; Alex Y Tan; Juan Song; Ghassan Gholmieh; Michael C Fishbein; Huai Luo; Robert J Siegel; Hrayr S Karagueuzian; Lan S Chen; Shien-Fong Lin; Peng-Sheng Chen Journal: J Am Coll Cardiol Date: 2007-07-10 Impact factor: 24.094
Authors: Sophie C Hofferberth; Frank Cecchin; Dan Loberman; Francis Fynn-Thompson Journal: J Thorac Cardiovasc Surg Date: 2013-10-24 Impact factor: 5.209
Authors: Dongze Zhang; Huiyin Tu; Chaojun Wang; Liang Cao; Robert L Muelleman; Michael C Wadman; Yu-Long Li Journal: Front Neurosci Date: 2017-05-08 Impact factor: 4.677
Authors: Cheryl M J Tan; Peregrine Green; Nidi Tapoulal; Adam J Lewandowski; Paul Leeson; Neil Herring Journal: Front Physiol Date: 2018-09-19 Impact factor: 4.566
Authors: Dongze Zhang; Wenfeng Hu; Huiyin Tu; Bryan T Hackfort; Bin Duan; Wanfen Xiong; Michael C Wadman; Yu-Long Li Journal: Basic Res Cardiol Date: 2021-04-21 Impact factor: 17.165